According to an announcement by the pharmaceutical company, Johnson & Johnson (JNJ) will invest over $55 billion in various healthcare sectors in the U.S. during the next four years, including a major North Carolina facility. That would mark an increase of 25 percent compared with the previous four years.

The investments will be spread across research and development, innovation powerhouse, announced manufacturing, and technology. This is headlined by a $2 billion biologics manufacturing development facility in Wilson, North Carolina, which recently broke the ground. The 500,000-square-foot site is expected to create 5,000 jobs during the construction phase and more than 500 employment opportunities in the state. Moreover, it is set to expand medication capacity for those with neurological diseases and cancer and provide an estimated $3 billion economic impact during the first decade open in North Carolina.

Aside from the specific development in Wilson, JNJ is planning three more manufacturing facilities and improving its locations under its Innovative Medicine and MedTech segment. Also, the New Brunswick, New Jersey-based firm plans to invest specifically in speeding up drug development and research for treatments ranging from cardiovascular disease to neuroscience, oncology, robotic surgery, and immunology.